[1]Fish,PaulV.;Filippakopoulos,Panagis;Bish,Gerwyn;Brennan,PaulE.;Bunnage,MarkE.;Cook,AndrewS.;Federov,Oleg;Gerstenberger,BrianS.;Jones,Hannah;Knapp,Stefan;Marsden,Brian;Nocka,Karl;Owen,DafyddR.;Philpott,Martin;Picaud,Sarah;Primiano,MichaelJ.;Ralph,MichaelJ.;Sciammetta,Nunzio;Trzupek,JohnD.[JournalofMedicinalChemistry,2012,vol.55,#22,p.9831-9837]
[2]CurrentPatentAssignee:PFIZERINC-WO2013/27168,2013,A1
[1]JournalofMedicinalChemistry,2012,vol.55,p.9831-9837
[1]CurrentPatentAssignee:PFIZERINC-WO2013/27168,2013,A1
[1]Patent:WO2013/27168,2013,A1.Locationinpatent:Page/Pagecolumn55
Title: BRD4 is a novel therapeutic target for liver fibrosis.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20151222
Title: Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells.
Journal: PloS one 20140101
Title: Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
Journal: Journal of medicinal chemistry 20130425
Title: Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
Journal: Journal of medicinal chemistry 20121126
Title: Picaud S, et al. PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. Cancer Res. 2013 May 21. [Epub ahead of print
Title: Fish PV, et al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012 Nov 26;55(22):9831-7.
Title: Cheng Z, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res. 2013 Apr 1;19(7):1748-59.
Title: Kate E Lines, et al. Epigenetic modifiers reduce proliferation of human neuroendocrine tumour cell lines. Endocrine Abstracts (2013) 31 P149
